Efficacy and safety of methylprednisolone assisted with thalidomide in the treatment of refractory rash in SLE
Objective:To investigate the clinical application effect of methylprednisolone assisted with thalidomide in the treatment of refractory rash in systemic lupus erythematosus(SLE).Methods:From January 2022 to October 2023,69 patients with SLE and refractory rashes admitted to the hospital were selected as the research subjects.They were divided into the control group(32 cases)and the combination group(37 cases)according to different treatment methods.The former was treated with thalidomide,and the latter was treated with methylprednisolone on this basis.Compare the clinical efficacy,disease activity,and immune function of two groups of patients before and after treatment,and record the occurrence of adverse reactions during the treatment period.Results:The total effective rates in the combination group and the control group were 94.59%(25/37)and 78.13%(25/32),and the former was significantly higher(P<0.05).After treatment,Systemic Lupus Erythematosus Disease Activity Index(SLEDAI)scores of both groups were lower than those before treatment,and scores of the combination group were significantly lower(P<0.05).After 3 months of treatment,there were increases in the levels of complement C3 and complement C4,and decreases in the levels of immunoglobulin(Ig)A,IgG and IgM in both groups.The changes were greater in the combination group(P<0.05).In terms of safety,the two groups were comparable(P>0.05).Conclusion:Compared with treatment with thalidomide alone,combined treatment with methylprednisolone and thalidomide is more effective for patients with SLE and refractory rashes,which can improve disease activity and immune function,with safety.
NETL
NSTL
万方数据
